Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy (Q34122646)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy |
scientific article |
Statements
1 reference
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy (English)
1 reference
Bart Barlogie
1 reference
Sarah Waheed
1 reference
Antje Hoering
1 reference
Elias Anaissie
1 reference
Jackie Szymonifka
1 reference
Bijay Nair
1 reference
Yazan Alsayed
1 reference
Nathan Petty
1 reference
John D Shaughnessy
1 reference
John Crowley
1 reference
25 May 2010
1 reference
1 reference
116
1 reference
1220-1227
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference